Scholar Rock Holding Corporation - Common Stock (SRRK)
30.82
+0.03 (0.10%)
NASDAQ · Last Trade: Nov 12th, 8:46 PM EST
Detailed Quote
Previous Close
30.79
Open
30.80
Bid
27.17
Ask
31.70
Day's Range
30.35 - 31.46
52 Week Range
22.71 - 46.98
Volume
1,285,652
Market Cap
2.92B
PE Ratio (TTM)
-10.55
EPS (TTM)
-2.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,676,803
Chart
About Scholar Rock Holding Corporation - Common Stock (SRRK)
Scholar Rock Holding Corp is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases, particularly those related to muscle and neuromuscular disorders. The company's proprietary approach leverages its knowledge of the biology underlying certain conditions to identify and target specific proteins that play a critical role in disease progression. By developing these targeted therapies, Scholar Rock aims to offer new, effective treatment options for patients who currently have limited alternatives. The company is dedicated to advancing its research and clinical programs while fostering collaboration within the scientific and medical communities. Read More
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857 shares of its common stock.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Tuesday, November 18 at 3:30 p.m. GMT in London, UK.
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open.
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the company granted inducement equity awards covering an aggregate of 114,500 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,429 shares of common stock and inducement restricted stock units, covering an aggregate of 49,071 shares of its common stock.
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) for the treatment of patients with spinal muscular atrophy (SMA). The CRL is related to observations identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility which was acquired by Novo Nordisk A/S in December 2024. The observations are not specific to apitegromab. The CRL did not cite any other approvability concerns, including apitegromab’s efficacy and safety data or the third-party drug substance manufacturer.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock.
